Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX
Annals of the Rheumatic Diseases · 2024-10 · 83 (10) · 1358-1367
DOI: 10.1136/ard-2024-225640 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2024-10. Verfasst von Jerome Hadjadj und 59 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, service de médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, France jerome.hadjadj@aphp.fr sophie.georgin-lavialle@aphp.fr. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Ubiquitin-Activating Enzymes, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: Vacuoles, E1 enzyme, X-linked, autoinflammatory and somatic (VEXAS) syndrome is an adult-onset autoinflammatory disease associated with somatic ubiquitin-like modifier-activating enzyme 1 (UBA1) mutations. We aimed to evaluate the efficacy and safety of targeted therapies. METHODS: Multicentre retrospective study including patients with genetically proven VEXAS syndrome who had received at least one targeted therapy. Complete response (CR) was defined by a clinical remission, C-reactive protein (CRP) ≤10 mg/L and a ≤10 mg/day of prednisone-equivalent therapy, and partial response (PR) was defined by a clinical remission and a 50% reduction in CRP levels and glucocorticoid dose. RESULTS: 110 patients (median age 71 (68-79) years) who received 194 targeted therapies were included: 78 (40%) received Janus kinase (JAK) inhibitors (JAKi), 51 (26%) interleukin (IL)-6 inhibitors, 33 (17%) IL-1 inhibitors, 20 (10%) tumour necrosis factor (TNFα) blockers and 12 (6%) other targeted therapies. At 3 months, the overall response (CR and PR) rate was 24% with JAKi, 32% with IL-6 inhibitors, 9% with anti-IL-1 and 0% with TNFα blockers or other targeted therapies. At 6 months, the overall response rate was 30% with JAKi and 26% with IL-6 inhibitors. Survival without treatment discontinuation was significantly longer with JAKi than with the other targeted therapies. Among patients who discontinued treatment, causes were primary failure, secondary failure, serious adverse event or death in 43%, 14%, 19% and 19%, respectively, with JAKi and 46%, 11%, 31% and 9%, respectively, with IL-6 inhibitors. CONCLUSIONS: This study shows the benefit of JAKi and IL-6 inhibitors, whereas other therapies have lower efficacy. These results need to be confirmed in prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, service de médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, France jerome.hadjadj@aphp.fr sophie.georgin-lavialle@aphp.fr.
- Service de médecine interne, Hôpital Beaujon, AP-HP.Nord, Université Paris Cité, Clichy, France.
- Sorbonne Université, service de médecine interne, Hôpital Saint-Antoine, AP-HP, Paris, France.
- Médecine Interne, CEREMAIA, Sorbonne Université, Hospital Tenon, Paris, France.
- Université Tunis el Manar, Faculté de médecine de Tunis, Tunis, Tunisia.
- Hématologie, Hôpital Lyon Sud - HCL, Pierre-Bénite, France.
ORCID-Profile: Jerome Hadjadj, Yann Nguyen, Corrado Campochiaro, Cyrille Coustal, Yvan Jamilloux, Maxime Samson, Etienne Crickx, Paul Decker, Thomas Moulinet, Anael Dumont, Laurent Arnaud, Thibaud Chazal
Zitieren
APA
Hadjadj, J., Nguyen, Y., Mouloudj, D., Bourguiba, R., Heiblig, M., Aloui, H., McAvoy, C., Lacombe, V., Ardois, S., Campochiaro, C., Maria, A., Coustal, C., Comont, T., Lazaro, E., Lifermann, F., Le Guenno, G., Lobbes, H., Grobost, V., Outh, R., …, & Chazal, T. (2024). Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Annals of the Rheumatic Diseases, 83(10), 1358-1367. https://doi.org/10.1136/ard-2024-225640
Vancouver
Hadjadj J, Nguyen Y, Mouloudj D, Bourguiba R, Heiblig M, Aloui H, et al. Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX. Annals of the Rheumatic Diseases. 2024;83(10):1358-1367. doi:10.1136/ard-2024-225640
BibTeX
@article{Hadjadj2024,
author = {Hadjadj, Jerome and Nguyen, Yann and Mouloudj, Dalila and Bourguiba, Rim and Heiblig, Mael and Aloui, Hassina and McAvoy, Chloe and Lacombe, Valentin and Ardois, Samuel and Campochiaro, Corrado and Maria, Alexandre and Coustal, Cyrille and Comont, Thibault and Lazaro, Estibaliz and Lifermann, Francois and Le Guenno, Guillaume and Lobbes, Hervé and Grobost, Vincent and Outh, Roderau and Campagne, Julien and Dor-Etienne, Anais and Garnier, Alice and Jamilloux, Yvan and Dossier, Antoine and Samson, Maxime and Audia, Sylvain and Nicolas, Barbara and Mathian, Alexis and de Maleprade, Baptiste and De Sainte-Marie, Benjamin and Faucher, Benoit and Bouaziz, Jean-David and Broner, Jonathan and Dumain, Cyril and Antoine, Carole and Carpentier, Benjamin and Castel, Brice and Lartigau-Roussin, Celine and Crickx, Etienne and Volle, Geoffroy and Fayard, Damien and Decker, Paul and Moulinet, Thomas and Dumont, Anael and Nguyen, Alexandre and Aouba, Achille and Martellosio, Jean-Philippe and Levavasseur, Matthieu and Puigrenier, Sebastien and Antoine, Pascale and Giraud, Jean-Thomas and Hermine, Olivier and Lacout, Carole and Martis, Nihal and Karam, Jean-Denis and Chasset, Francois and Arnaud, Laurent and Marianetti, Paola and Deligny, Christophe and Chazal, Thibaud},
title = {Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX},
journal = {Annals of the Rheumatic Diseases},
year = {2024},
volume = {83},
number = {10},
pages = {1358--1367},
doi = {10.1136/ard-2024-225640}
}
EUVIMED